CA1314229C - Treatment of lipoprotein disorders associated with cholesterol metabolism - Google Patents
Treatment of lipoprotein disorders associated with cholesterol metabolismInfo
- Publication number
- CA1314229C CA1314229C CA000580218A CA580218A CA1314229C CA 1314229 C CA1314229 C CA 1314229C CA 000580218 A CA000580218 A CA 000580218A CA 580218 A CA580218 A CA 580218A CA 1314229 C CA1314229 C CA 1314229C
- Authority
- CA
- Canada
- Prior art keywords
- blackcurrant
- cholesterol
- treatment
- disorders associated
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 32
- 102000004895 Lipoproteins Human genes 0.000 title claims abstract description 11
- 108090001030 Lipoproteins Proteins 0.000 title claims abstract description 11
- 230000004060 metabolic process Effects 0.000 title claims abstract description 7
- 239000010473 blackcurrant seed oil Substances 0.000 claims abstract description 5
- 235000001466 Ribes nigrum Nutrition 0.000 claims description 12
- 235000016954 Ribes hudsonianum Nutrition 0.000 claims description 11
- 150000002632 lipids Chemical class 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 7
- 235000005911 diet Nutrition 0.000 claims description 4
- 230000000378 dietary effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 240000001890 Ribes hudsonianum Species 0.000 claims 4
- 235000012000 cholesterol Nutrition 0.000 abstract description 10
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract description 7
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 5
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 2
- 229940107161 cholesterol Drugs 0.000 description 11
- 241001312569 Ribes nigrum Species 0.000 description 8
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 6
- 239000008169 grapeseed oil Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 3
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 3
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 3
- 229960002733 gamolenic acid Drugs 0.000 description 3
- 229960004488 linolenic acid Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102100034544 Acyl-CoA 6-desaturase Human genes 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 108010037138 Linoleoyl-CoA Desaturase Proteins 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- 208000034599 Dysbetalipoproteinemia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 201000010252 Hyperlipoproteinemia Type III Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 206010060751 Type III hyperlipidaemia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical class OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940094199 black currant oil Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- QWUFXJHVFNRNCU-UHFFFAOYSA-N phenazin-1-amine Chemical compound C1=CC=C2N=C3C(N)=CC=CC3=NC2=C1 QWUFXJHVFNRNCU-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH4069/87A CH673223A5 (enrdf_load_stackoverflow) | 1987-10-16 | 1987-10-16 | |
| CH4069/87-0 | 1987-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1314229C true CA1314229C (en) | 1993-03-09 |
Family
ID=4269238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000580218A Expired - Fee Related CA1314229C (en) | 1987-10-16 | 1988-10-14 | Treatment of lipoprotein disorders associated with cholesterol metabolism |
Country Status (10)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6325289U (enrdf_load_stackoverflow) * | 1986-07-31 | 1988-02-19 | ||
| CH676909A5 (enrdf_load_stackoverflow) * | 1988-12-23 | 1991-03-28 | Nestle Sa | |
| JP2917037B2 (ja) * | 1990-01-09 | 1999-07-12 | 株式会社アドバンス | Ａｃａｔ阻害剤 |
| US6667064B2 (en) * | 2000-08-30 | 2003-12-23 | Pilot Therapeutics, Inc. | Composition and method for treatment of hypertriglyceridemia |
| JP2006014730A (ja) * | 2004-05-31 | 2006-01-19 | Toyo Shinyaku:Kk | 食品 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2834227A1 (de) * | 1978-08-04 | 1980-02-28 | Merck Patent Gmbh | Hypo- beta -lipoproteinaemisches diaetetikum, verfahren zu seiner herstellung und verwendung |
| DE3368377D1 (en) * | 1982-04-16 | 1987-01-29 | Nestle Sa | Lipid composition for oral, enteral or parenteral feeding |
| JPS61118318A (ja) * | 1984-11-12 | 1986-06-05 | Pola Chem Ind Inc | 血清脂質改善用組成物 |
-
1987
- 1987-10-16 CH CH4069/87A patent/CH673223A5/fr not_active IP Right Cessation
-
1988
- 1988-10-03 AT AT88116343T patent/ATE72987T1/de not_active IP Right Cessation
- 1988-10-03 EP EP88116343A patent/EP0311866B1/fr not_active Expired - Lifetime
- 1988-10-03 ES ES198888116343T patent/ES2036650T3/es not_active Expired - Lifetime
- 1988-10-03 DE DE8888116343T patent/DE3868827D1/de not_active Expired - Fee Related
- 1988-10-03 IE IE298988A patent/IE61682B1/en not_active IP Right Cessation
- 1988-10-05 AU AU23433/88A patent/AU611204B2/en not_active Ceased
- 1988-10-14 CA CA000580218A patent/CA1314229C/en not_active Expired - Fee Related
- 1988-10-14 JP JP63257453A patent/JPH075471B2/ja not_active Expired - Lifetime
-
1992
- 1992-03-05 GR GR920400345T patent/GR3003990T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH075471B2 (ja) | 1995-01-25 |
| JPH01132530A (ja) | 1989-05-25 |
| EP0311866A1 (fr) | 1989-04-19 |
| IE882989L (en) | 1989-04-16 |
| AU2343388A (en) | 1989-04-20 |
| DE3868827D1 (de) | 1992-04-09 |
| EP0311866B1 (fr) | 1992-03-04 |
| ES2036650T3 (es) | 1993-06-01 |
| CH673223A5 (enrdf_load_stackoverflow) | 1990-02-28 |
| GR3003990T3 (enrdf_load_stackoverflow) | 1993-03-16 |
| ATE72987T1 (de) | 1992-03-15 |
| IE61682B1 (en) | 1994-11-16 |
| AU611204B2 (en) | 1991-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Davidson et al. | Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial. | |
| AU2003229993B2 (en) | Use of EPA and DHA in secondary prevention | |
| PAUL et al. | On the mechanism of hypocholesterolemic effects of polyunsaturated lipids | |
| US5059622A (en) | Method for reducing blood pressure levels in hypertensive persons | |
| AU653353B2 (en) | Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using | |
| US20110015160A1 (en) | Methods of treating neurological diseases using docosahexaenoic acid and arachidonic acid compositions | |
| EP0321128A1 (en) | Fatty acid compositions | |
| Berr et al. | Dietary N‐3 polyunsaturated fatty acids decrease biliary cholesterol saturation in gallstone disease | |
| AU5182800A (en) | Methods for controlling highly unsaturated fatty acid content in various tissues | |
| EP0524796A1 (en) | Use of essential fatty acids in the preparation of a medicament for the treatment of AIDS | |
| US8729124B2 (en) | Use of EPA and DHA in secondary prevention | |
| US4999380A (en) | Treatment of lipoprotein disorders associated with cholesterol metabolism | |
| EP0201159B1 (en) | Pharmaceutical and dietary compositions containing linolenic acids for the treatment of benign prostatic hypertrophy | |
| Bierenbaum et al. | Effects of canola oil on serum lipids in humans. | |
| Radack et al. | n-3 fatty acid effects on lipids, lipoproteins, and apolipoproteins at very low doses: results of a randomized controlled trial in hypertriglyceridemic subjects | |
| CA1314229C (en) | Treatment of lipoprotein disorders associated with cholesterol metabolism | |
| Svaneborg et al. | The acute effects of a single very high dose of n− 3 fatty acids on plasma lipids and lipoproteins in healthy subjects | |
| Miller et al. | Triglyceride lowering effect of MaxEPA fish lipid concentrate: a multicentre placebo controlled double blind study | |
| JP2005529903A (ja) | 脳卒中等における二次的な脳疾患事象についてのエイコサペンタエン酸（ｅｐａ）およびドコサヘキサエン酸（ｄｈａ）の使用 | |
| Lundholm et al. | Influence of nicotinic acid, niceritrol and β-pyridylcarbinol on experimental hyperlipidemia and atherosclerosis in mini-pigs | |
| CA1334002C (en) | Essential fatty acid compositions and methods for the modulation of prostaglandin levels in mammals | |
| Daher et al. | Effect of acute and chronic moderate alcohol consumption on fasted and postprandial lipemia in the rat | |
| Kritchevsky | Conjugated linoleic acid and experimental atherosclerosis in rabbits | |
| AU2005244483B2 (en) | Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease | |
| Mustafa | Study of Effects of Cigarette Smoking on Lipid Profile in the Young Subjects Attending AMCH, Vijayapur |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |